Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On August 13, 2021, Ronald Vigliotta, the Vice President, Finance and principal
accounting officer of Decibel Therapeutics, Inc. (the "Company"), notified the
Company that he is resigning from his position, effective as of September 9,
2021. Mr. Vigliotta informed the Company that his resignation is not related to
any disagreement with the Company on any matter relating to the Company's
operations, policies or practices.
Elisabeth Leiderman, the Company's Chief Financial Officer and Head of Corporate
Development, will serve as the Company's principal accounting officer, effective
as of September 9, 2021. Dr. Leiderman, 44, has served as the Company's Chief
Financial Officer and Head of Corporate Development since joining the Company in
September 2020. Prior to joining the Company, from January 2020 to August 2020,
Dr. Leiderman served as chief business officer at Complexa, Inc., a
biopharmaceutical company. From November 2016 to November 2019, she was senior
vice president, head of corporate development at Fortress Biotech, Inc., a
biopharmaceutical company. She was a healthcare investment banker from 2007 to
2016. Most recently, she was an executive director at Nomura Securities, an
investment bank, from 2013 to July 2016. Dr. Leiderman received a B.A. in
biological sciences from the University of Pennsylvania, an M.B.A. from The
Wharton School of the University of Pennsylvania and an M.D. from the Sackler
School of Medicine at Tel Aviv University.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
DECIBEL THERAPEUTICS, INC. 
